385 related articles for article (PubMed ID: 25626317)
21. Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells.
Foltankova V; Legartova S; Kozubek S; Bartova E
Neoplasma; 2012; 59(4):450-62. PubMed ID: 22489701
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
23. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic regulation and cancer (review).
Chen QW; Zhu XY; Li YY; Meng ZQ
Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.
Gkotzamanidou M; Terpou E; Kentepozidis N; Terpos E
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638744
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.
Glajch KE; Sadri-Vakili G
J Huntingtons Dis; 2015; 4(1):1-15. PubMed ID: 25813218
[TBL] [Abstract][Full Text] [Related]
27. Epigenomes as therapeutic targets.
Hamm CA; Costa FF
Pharmacol Ther; 2015 Jul; 151():72-86. PubMed ID: 25797698
[TBL] [Abstract][Full Text] [Related]
28. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
Bruyer A; Maes K; Herviou L; Kassambara A; Seckinger A; Cartron G; Rème T; Robert N; Requirand G; Boireau S; Müller-Tidow C; Veyrune JL; Vincent L; Bouhya S; Goldschmidt H; Vanderkerken K; Hose D; Klein B; De Bruyne E; Moreaux J
Br J Cancer; 2018 Apr; 118(8):1062-1073. PubMed ID: 29500406
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
Maharaj L; Marson CM; Middleton BJ; Rioja AS; Perry J; Oakervee H; Cavenagh J; Joel SP; Popat R
Br J Haematol; 2013 Oct; 163(1):135-9. PubMed ID: 23834265
[No Abstract] [Full Text] [Related]
31. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic targeting in pancreatic cancer.
van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
[TBL] [Abstract][Full Text] [Related]
33. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic drugs in Alzheimer's disease.
Cuadrado-Tejedor M; Oyarzabal J; Lucas MP; Franco R; García-Osta A
Biomol Concepts; 2013 Oct; 4(5):433-45. PubMed ID: 25436752
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic therapy in hematological cancers.
Dimopoulos K; Grønbaek K
APMIS; 2019 May; 127(5):316-328. PubMed ID: 30859683
[TBL] [Abstract][Full Text] [Related]
36. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.
Jia H; Morris CD; Williams RM; Loring JF; Thomas EA
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E56-64. PubMed ID: 25535382
[TBL] [Abstract][Full Text] [Related]
38. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
[TBL] [Abstract][Full Text] [Related]
39. Current and potential epigenetic targets in multiple myeloma.
Pawlyn C; Kaiser MF; Davies FE; Morgan GJ
Epigenomics; 2014 Apr; 6(2):215-28. PubMed ID: 24811790
[TBL] [Abstract][Full Text] [Related]
40. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
